Apoptosis and melanoma chemoresistance
Top Cited Papers
- 19 May 2003
- journal article
- review article
- Published by Springer Nature in Oncogene
- Vol. 22 (20) , 3138-3151
- https://doi.org/10.1038/sj.onc.1206454
Abstract
Melanoma is the most aggressive form of skin cancer and is notoriously resistant to all current modalities of cancer therapy. A large set of genetic, functional and biochemical studies suggest that melanoma cells become ‘bullet proof’ against a variety of chemotherapeutic drugs by exploiting their intrinsic resistance to apoptosis and by reprogramming their proliferation and survival pathways during melanoma progression. In recent years, the identification of molecules involved in the regulation and execution of apoptosis, and their alteration in melanoma, have provided new insights into the molecular basis for melanoma chemoresistance. With this knowledge in hand, the challenge is now to devise strategies potent enough to compensate or bypass these cell death defects and improve the actual poor prognosis of patients at late stages of the disease.Keywords
This publication has 163 references indexed in Scilit:
- RNA interferenceNature, 2002
- Mutations of the BRAF gene in human cancerNature, 2002
- IAP proteins: blocking the road to death's doorNature Reviews Molecular Cell Biology, 2002
- NF-κB at the crossroads of life and deathNature Immunology, 2002
- Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communicationOncogene, 2001
- Selective Expression of FLIP in Malignant Melanocytic Skin LesionsJournal of Investigative Dermatology, 2001
- Long-term prognostic significance of HSP-70, c-myc and HLA-DR expression in patients with malignant melanomaEuropean Journal of Surgical Oncology, 2001
- The Hallmarks of CancerCell, 2000
- Expression and Targeting of the Apoptosis Inhibitor, Survivin, in Human MelanomaJournal of Investigative Dermatology, 1999
- Programmed Cell Death in Animal DevelopmentCell, 1997